ARVN News and Press, Arvinas Inc. From 10/17/19

Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 Trials Neuroscience Presentation to Include Data from Preclinical Tau and Alpha-Synuclein Programs NEW HAVEN, Conn., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc., (Nasdaq...

NEW HAVEN, Conn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new thought leaders will join the company’s scientific advisory board (SAB). The new membe...

Bayer ( OTCPK:BAYZF ) and Arvinas (NASDAQ: ARVN ) say they have finalized the terms of their agreement to jointly launch a new company called Oerth Bio. More news on: Arvinas, Inc., Bayer Aktiengesellschaft, Healthcare stocks news, Merger & acquisition news, Read more ......

- Oerth Bio to utilize Arvinas’ PROTAC® technology to develop innovative new agricultural products to improve crop yields - John Dombrosky Announced as CEO of Oerth Bio - Transaction had been formally closed on July 15, 2019 MONHEIM, Germany and BOSTON and NEW HAVEN, ...

Arvinas (NASDAQ: ARVN ) initiated with Outperform rating and $38 (61% upside) price target at Wedbush. More news on: Arvinas, Inc., Minerva Neurosciences, Inc., Strongbridge Biopharma plc, Healthcare stocks news, Stocks on the move, , Read more ...

ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Buy rating and $76 (9% upside) price target at Guggenheim. More news on: ANI Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Arvinas (NASDAQ: ARVN ) initiates its second clinical program with the launch of a Phase 1 study assessing ARV-471 in patients with locally advanced/metastatic ER+/HER2- breast cancer. Preliminary data should be available in 2020. More news on: Arvinas, Inc., Healthcare stocks news, ...

NEW HAVEN, Conn., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the initiation of patient dosing in its second clinical program. The Phase 1 clinical trial of ARV-4...

NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the company is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on W...

Arvinas (NASDAQ: ARVN ): Q2 GAAP EPS of -$0.55 misses by $0.14 . Revenue of $4.01M (+17.9% Y/Y) beats by $0.32M . Press Release More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news,